title: Testicular neoplasms: seminoma.
abstract: From 1969 to 1984, 58 patients with a diagnosis of testicular seminoma were seen and treated at the University of Kansas Medical Center. The median age was 34 years (range of 20 to 62 years). The American Joint Committee on Cancer Staging System was followed: stage I (34 patients); stage II (6); stage III (8); and stage IV (10). Forty-two patients had typical seminoma, and 16 had anaplastic histology. Nine patients had elevated B subunit of human chorionic gonadotropin, and nine had a history of cryptorchidism. Fifty-six patients received radiation treatment, and seven received chemotherapy with or without radiation. The median follow-up was 7 years (range 3 to 16 years). The overall disease-free (absolute) survival according to stage was: stage I, 91% (100%); stage II, 66% (80%); stage III, 75% (85%); and stage IV, 50% (50%). There were no late complications. The survival for patients with anaplastic histology or with elevated B subunit of human chorionic gonadotropin was not significantly different from that of typical seminoma.
authors.affiliation: Department of Radiation Oncology, University of Kansas Medical Center, Kansas City 66103.
authors.forename: E K
authors.initials: EK
authors.lastname: Reddy
authors.forename: M
authors.initials: M
authors.lastname: Burke
authors.forename: S
authors.initials: S
authors.lastname: Giri
authors.forename: L
authors.initials: L
authors.lastname: Krishnan
authors.forename: L
authors.initials: L
authors.lastname: Gemer
authors.forename: R
authors.initials: R
authors.lastname: Evans
authors.forename: W K
authors.initials: WK
authors.lastname: Mebust
authors.forename: J
authors.initials: J
authors.lastname: Wiegel
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D007615:Kansas / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011882:Radiotherapy, High-Energy; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000453:epidemiology / Q000628:therapy